Jefferies Financial Group Boosts Edwards Lifesciences (EW) Price Target to $180.00

Edwards Lifesciences (NYSE:EW) had its price target increased by research analysts at Jefferies Financial Group from $168.00 to $180.00 in a research note issued to investors on Thursday, Marketbeat reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Jefferies Financial Group’s price target suggests a potential upside of 14.50% from the company’s previous close. Jefferies Financial Group also issued estimates for Edwards Lifesciences’ Q1 2019 earnings at $1.35 EPS, Q2 2019 earnings at $1.33 EPS, Q4 2019 earnings at $1.29 EPS, FY2019 earnings at $5.22 EPS, FY2020 earnings at $5.86 EPS, FY2021 earnings at $6.57 EPS and FY2022 earnings at $7.42 EPS.

A number of other equities research analysts also recently weighed in on EW. ValuEngine downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 8th. SunTrust Banks cut their target price on Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a research report on Friday, August 10th. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research report on Wednesday, September 26th. Guggenheim downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 2nd. Finally, Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 2nd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $162.85.

Shares of EW stock opened at $157.21 on Thursday. The company has a market capitalization of $34.14 billion, a P/E ratio of 41.37, a price-to-earnings-growth ratio of 2.15 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.31 and a quick ratio of 1.85. Edwards Lifesciences has a 12-month low of $110.68 and a 12-month high of $175.00.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.05. The firm had revenue of $906.60 million during the quarter, compared to the consensus estimate of $927.56 million. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.84 earnings per share. Equities research analysts forecast that Edwards Lifesciences will post 4.7 EPS for the current fiscal year.

In other news, VP Catherine M. Szyman sold 700 shares of the stock in a transaction on Monday, October 15th. The stock was sold at an average price of $142.64, for a total transaction of $99,848.00. Following the completion of the sale, the vice president now owns 27,772 shares in the company, valued at approximately $3,961,398.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Huimin Wang sold 3,800 shares of the stock in a transaction on Thursday, December 6th. The shares were sold at an average price of $155.87, for a total value of $592,306.00. Following the sale, the vice president now owns 35,024 shares of the company’s stock, valued at approximately $5,459,190.88. The disclosure for this sale can be found here. Insiders have sold a total of 187,156 shares of company stock valued at $27,603,513 in the last quarter. Insiders own 1.84% of the company’s stock.

Several large investors have recently made changes to their positions in EW. Belpointe Asset Management LLC raised its stake in Edwards Lifesciences by 21.3% during the 3rd quarter. Belpointe Asset Management LLC now owns 3,793 shares of the medical research company’s stock valued at $660,000 after purchasing an additional 665 shares during the period. B. Riley Wealth Management Inc. acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at $1,737,000. Neuberger Berman Group LLC raised its stake in Edwards Lifesciences by 1.9% during the 3rd quarter. Neuberger Berman Group LLC now owns 693,707 shares of the medical research company’s stock valued at $120,774,000 after purchasing an additional 13,260 shares during the period. Disciplined Growth Investors Inc. MN raised its stake in Edwards Lifesciences by 1.8% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,063,704 shares of the medical research company’s stock valued at $359,291,000 after purchasing an additional 36,418 shares during the period. Finally, Kentucky Retirement Systems acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at $594,000. Institutional investors own 82.55% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Read More: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit